Senseonics presents real-world Eversense 365 data at ADA 2026
Senseonics has presented expanded real-world evidence for its Eversense 365 implantable continuous glucose monitoring (CGM) system at the American Diabetes Association's 2026 Scientific Sessions in New Orleans, reporting sustained accuracy and high patient adherence over a full year of sensor use.
The dataset — drawn from 12,360 sensors in open-loop users and an additional 153 sensors used within the twiist automated insulin delivery (AID) system for more than 30 days — builds on findings Senseonics shared earlier this year at the ATTD conference. The enlarged cohort reinforces the company's central claim: that a single implanted sensor can deliver consistent performance across an entire year without the interruptions associated with short-duration wearable CGM patches.
Glucometric outcomes
Open-loop users recorded a mean Glucose Management Indicator (GMI) of 7.16% and a mean Time in Range (TIR) of 66.16%, with average transmitter wear time of 93.19%. Critically, outcomes across the first and second six-month periods were described as comparable, suggesting that sensor accuracy does not meaningfully degrade over time. More than 81% of users met established hypoglycaemic targets, a figure the company argues compares favourably with published real-world data for rival CGM systems, which have reported TIR ranging from 41.7% to 70.8%.
For the smaller closed-loop cohort using Eversense 365 alongside the twiist AID system, mean TIR reached approximately 76.08% and GMI fell to 6.78% after the first 30 days following pump pairing, with median sensor wear time of 99.46%. The company said these figures sit at the upper end of performance ranges reported for established AID systems in real-world settings.
Francine Kaufman, Chief Medical Officer at Senseonics, said the data "showcases the positive impact that Eversense 365 is bringing to patients, regardless of their preferred treatment plan," and noted that it "performs exceptionally well over an extended period."
Market context
The CGM market is intensely competitive, dominated by Dexcom and Abbott, whose G7 and FreeStyle Libre 3 platforms have broad installed bases and established reimbursement pathways in the US and Europe. Senseonics occupies a distinct niche as the sole provider of an implantable, long-duration sensor; the year-long wear period addresses a frequently cited patient complaint about the fortnightly or monthly replacement burden of patch-style devices.
The integration with the twiist AID system — developed by Sequel Med Tech — represents Senseonics' first closed-loop partnership and is strategically significant. The AID segment is widely regarded as the fastest-growing area of diabetes technology, with regulators and payers increasingly focused on real-world glycaemic outcomes as a condition of coverage decisions. Senseonics' ability to demonstrate competitive TIR data in a closed-loop context could strengthen the case for broader reimbursement, particularly as health technology assessment bodies in the UK and Europe examine long-term CGM options.
The dataset presented at ADA remains observational and the closed-loop cohort is small at 153 sensors, limiting the conclusions that can be drawn at this stage. Investors and clinicians will want to see a larger prospective dataset and, ultimately, head-to-head comparative evidence before drawing firm conclusions about the twiist integration's clinical standing relative to established AID platforms from Medtronic, Insulet and Tandem.